Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?

@article{Meltzer2008DoesSO,
  title={Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?},
  author={Herbert Y. Meltzer and Tomiki Sumiyoshi},
  journal={Behavioural Brain Research},
  year={2008},
  volume={195},
  pages={98-102}
}

Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT1A receptor activation

Serotonin-1A Receptors and Cognitive Enhancement in Schizophrenia: Role for Brain Energy Metabolism

TLDR
The prefrontal cortex has been considered to regulate various aspects of cognitive abilities, e.g. working memory, memory organization, executive function, and attention, and findings from electrophysiological studies suggest these cognitive benefits of 5-HT1A agonism are mediated by glutamate (Glu) and γaminobutyric acid (GABA) neurons.

Antipsychotic treatment modulates glutamate transport and NMDA receptor expression

TLDR
This review summarizes the current knowledge on effects of FGAs and SGAs on glutamate transport and receptor expression derived from pharmacological studies and indicates that serotonergic effects of SGAs represent important targets for further clinical research.

5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.

  • D. Haleem
  • Psychology, Biology
    Behavioural pharmacology
  • 2015
TLDR
This review concerns the role of 5-HT1A receptors in the modulation of nigrostriatal dopamine neurotransmission, with the aim of providing guidelines for future research to improve pharmacotherapy in schizophrenia and Parkinson's disease.

Neural activity, memory, and dementias: serotonergic markers

  • A. Meneses
  • Biology, Psychology
    Behavioural pharmacology
  • 2017
Dysfunctional memory seems to be a key component of diverse dementias and other neuropsychiatric disorders; unfortunately, no effective treatment exists for this, probably because of the absence of

New insight into the therapeutic role of 5-HT1A receptors in central nervous system disorders.

  • Y. Ohno
  • Biology, Psychology
    Central nervous system agents in medicinal chemistry
  • 2010
TLDR
New generation 5-HT(1A) ligands with greater potency, higher selectivity and improved pharmacokinetic properties are designed, which may overcome clinical efficacy limitations and/or improve adverse reactions in current CNS therapies.

Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research

TLDR
In agreement with pharmacological studies, presynaptic and postsynaptic 5- HT1A-R activation appears necessary for anxiolytic and antidepressant effects, respectively, yet, neurodevelopmental roles for 5-HT 1A-Rs are also involved.

Therapeutic Role of 5‐HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease

  • Y. Ohno
  • Psychology, Medicine
    CNS neuroscience & therapeutics
  • 2011
TLDR
Evidence that 5‐HT1A receptors seem to be a promising target for alleviating antipsychotic‐induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia and Parkinson's disease should encourage discovery of new 5‐ HT1A ligands, which can resolve the unmet clinical needs in the current therapy.
...

References

SHOWING 1-10 OF 72 REFERENCES

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

TLDR
There is now a sufficient rationale to examine thoroughly the role of the 5-HT1A receptor in schizophrenia and antipsychotic drug treatment, and the anticataleptic activity of 5- HT1A agonist augmentation of neuroleptics in the treatment of schizophrenia.

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders

TLDR
Evidence is provided for and against the use of selective 5-HT receptor drugs as cognition enhancing agents for schizophrenia and other disorders, and it is likely that serotonergic drugs will soon be available as cognition enhances medications for disorders other than schizophrenia.

Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

  • M. Millan
  • Psychology, Biology
    The Journal of pharmacology and experimental therapeutics
  • 2000
TLDR
Clinical studies of antipsychotics interacting with 5-HT(1A) receptors are required to establish their genuine pertinence to the-hopefully improved-treatment of schizophrenia.

Identification of a serotonin/glutamate receptor complex implicated in psychosis

TLDR
It is shown that the mGluR2 interacts through specific transmembrane helix domains with the 2AR, a member of an unrelated G-protein-coupled receptor family, to form functional complexes in brain cortex that may be involved in the altered cortical processes of schizophrenia.

Molecular targets for treating cognitive dysfunction in schizophrenia.

TLDR
Various molecular targets that are actively being explored for potential drug discovery efforts in schizophrenia and cognition are reviewed, including dopamine receptors in the prefrontal cortex, nicotinic and muscarinic acetylcholine receptors, the glutamatergic excitatory synapse, various serotonin receptors, and the gamma-aminobutyric acid system.

The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease.

TLDR
Receptor blockade by a 5-HT1A receptor antagonist appears to enhance activation and signaling through heterosynaptic neuronal circuits known to be involved in cognitive processes and, as such, represents a novel therapeutic approach to the treatment of cognitive deficits associated with Alzheimer s disease and potentially other disorders with underlying cognitive dysfunction.

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.

TLDR
Atypical antipsychotic drugs as a group appear to be superior to typical neuroleptics with regard to cognitive function, however, available data suggest that these drugs produce significant differences in specific cognitive functions.

Serotonin receptors : their key role in drugs to treat schizophrenia

Receptor and Transporter Imaging Studies in Schizophrenia, Depression, Bulimia and Tourette's Disorder—Implications for Psychopharmacology-

  • S. KasperJ. Tauscher T. Brücke
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2002
TLDR
It is demonstrated that atypical antipsychotics have a dose-dependent lower striatal D2 receptor occupancy rate compared with typical neuroleptics, paralleling the more favourable extrapyramidal side effects of atypicals antipsychotic side effects.
...